Login to Your Account



Medigene acquires Trianta for $5M up front, $8M milestones

By Cormac Sheridan
Staff Writer

Monday, January 27, 2014
Medigene AG is paying €4 million (US$5.5 million) in stock and could pay up to €5.875 million more in milestones to acquire newly formed start-up cancer immunotherapy firm Trianta Immunotherapies GmbH, which already has two clinical trials under way.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription